Headquartered in Dublin, Valitacell (https://www.valitacell.com/) is a biotechnology SME developing innovative technologies to aid and improve drug discovery and development. Founded in 2014, their main focus is on developing analytical technologies to assess key process parameters and product critical quality attributes in both biologics and cell therapy biomanufacturing. With thirteen employees, Valitacell’s combined knowledge of bioprocessing with deep learning and predictive analytics delivers an unprecedented and unique level of bioprocess performance.
Within AutoCRAT, Valitacell is developing their Quantum and ChemStress technology platforms for human mesenchymal stromal cell (hMSC) characterisation, focusing on hMSC secretome assessment and functional profiling during bioreactor-based expansion. These analytical tools will be fully automated within the AutoCRAT QC arm at the IPT Fraunhofer facility in Germany.
Valitacell Technologies: The Quantum platform underpins a range of simple, high-throughput target quantification and detection assays. It is based on fluorescence polarisation technology which we use to measure probe: target interactions. Fluorescence Polarisation-based detection can be performed on all multimode plate readers, and is fully automatable, thereby allowing fully scalable workflows. In AutoCRAT, Valitacell is investigating the use of their Quantum platform in hMSC secretome assessment, focusing on specific secreted factors of interest such as extracellular vesicles. ChemStress Fingerprinting is an information-rich, analytical assay supplying data on the functional quality of cells in specific culture media environments. This novel platform characterises cells using a panel of specific, small molecule chemical stressors to generate a unique biological signature or ‘Fingerprint’. Initially deployed in CHO based biomanufacturing cell line development and media QC, Valitacell is adapting this platform for hMSC functional profiling, with potential applications in donor release and acceptance as well as media and process development, and optimisation.
